| 1 |
Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis [J]. Arthritis Rheum, 2008, 59(9): 1207-1213.
|
| 2 |
Woolf AD, Pfleger B. Burden of major musculoskeletal conditions [J]. Bull World Health Organ, 2003, 81(9): 646-656.
|
| 3 |
Zeng SY, Gong Y, Zhang YP, et al. Changes in the prevalence of rheumatic diseases in shantou, China, in the past three decades: a COPCORD study [J]. PLoS One, 2015, 10(9): e0138492.
|
| 4 |
Skevington SM. Investigating the relationship between pain and discomfort and quality of Life, using the WHOQOL [J]. Pain, 1998, 76(3): 395-406.
|
| 5 |
Axford J, Heron C, Ross F, et al. Management of knee osteoarthritis in primary care: pain and depression are the major obstacles [J]. J Psychosom Res, 2008, 64(5): 461-467.
|
| 6 |
Lie HC, Hjermstad MJ, Fayers P, et al. Depression in advanced cancer--assessment challenges and associations with disease load [J]. J Affect Disord, 2015, 173: 176-184.
|
| 7 |
Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors [J]. Ann Intern Med, 2000, 133(8): 635-646.
|
| 8 |
Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice [J]. Lancet, 2011, 377(9783): 2115-2126.
|
| 9 |
Fingleton C, Smart K, Moloney N, et al. Pain sensitization in People with knee osteoarthritis: a systematic review and meta-analysis [J]. Osteoarthritis Cartilage, 2015, 23(7): 1043-1056.
|
| 10 |
Arendt-Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients with painful knee osteoarthritis [J]. Pain, 2010, 149(3): 573-581.
|
| 11 |
Dray A RS, pain. Future targets to control osteoarthritis pain [J]. Arthritis Res Ther, 2007, 9(3): 212.
|
| 12 |
Hochman JR, Gagliese L, Davis AM, et al. Neuropathic pain symptoms in a community knee OA cohort [J]. Osteoarthritis Cartilage, 2011, 19(6): 647-654.
|
| 13 |
Kim SH, Yoon KB, Yoon DM, et al. Influence of centrally mediated symptoms on postoperative pain in osteoarthritis patients undergoing total knee arthroplasty: a prospective observational evaluation [J]. Pain Pract, 2015, 15(6): E46-E53.
|
| 14 |
Ho KY, Tay W, Yeo MC, et al. Duloxetine reduces morphine requirements after knee replacement surgery [J]. Br J Anaesth, 2010, 105(3): 371-376.
|
| 15 |
Yadeau JT, Brummett CM, Mayman DJ, et al. Duloxetine and subacute pain after knee arthroplasty when added to a multimodal analgesic regimen: a randomized, placebo-controlled, triple-blinded trial [J]. Anesthesiology, 2016, 125(3): 561-572.
|
| 16 |
Woolf CJ, Thompson SW, King AE. Prolonged primary afferent induced alterations in dorsal Horn neurones, an intracellular analysis in vivo and in vitro [J]. J Physiol (Paris), 1988, 83(3): 255-266.
|
| 17 |
Muhammad BY. Central sensitivity syndromes: an overview [J]. J Musculoskelet Pain, 2009, 17(4): 400-408.
|
| 18 |
Kindler LL, Bennett RM, Jones KD. Central sensitivity syndromes: mounting pathophysiologic evidence to Link fibromyalgia with other common chronic pain disorders [J]. Pain Manag Nurs, 2011, 12(1): 15-24.
|
| 19 |
Smart KM, Blake C, Staines A, et al. The discriminative validity of "nociceptive," "peripheral neuropathic," and "central sensitization" as mechanisms-based classifications of musculoskeletal pain [J]. Clin J Pain, 2011, 27(8): 655-663.
|
| 20 |
Gracely R, Petzke F, Wolf J, et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia [J]. Arthritis Rheum, 2002, 46: 1333-1343
|
| 21 |
Yunus MB. nd group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness [J]. Semin Arthritis Rheum, 2008, 37(6): 339-352
|
| 22 |
Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes [J]. Semin Arthritis Rheum, 2007, 36(6): 339-356.
|
| 23 |
Giamberardino MA, Affaitati G, Fabrizio A, et al. Myofascial pain syndromes and their evaluation [J]. Best Practice & Research in Clinical Rheumatology, 2011, 25(2): 185-198.
|
| 24 |
Hubbard DR, Berkoff GM. Myofascial trigger points show spontaneous needle EMG activity [J]. Spine (Phila Pa 1976), 1993, 18(13): 1803-1807.
|
| 25 |
Mcnulty WH, Gevirtz RN, Hubbard DR, et al. Needle electromyographic evaluation of trigger point response to a psychological stressor [J]. Psychophysiology, 1994, 31(3): 313-316.
|
| 26 |
Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain [J]. Pain, 2011, 152(3 Suppl): S2-15.
|
| 27 |
Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation [J]. Neuron, 2007, 55(3): 377-391.
|
| 28 |
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity [J]. J Pain, 2009, 10(9): 895-926.
|
| 29 |
Phillips K, Clauw DJ. Central pain mechanisms in chronic pain states--maybe it is all in their head [J]. Best Pract Res Clin Rheumatol, 2011, 25(2): 141-154.
|
| 30 |
Yunus MB. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain [J]. Best Pract Res Clin Rheumatol, 2007, 21(3): 481-497.
|
| 31 |
Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Central hypersensitivity in chronic pain: mechanisms and clinical implications [J]. Phys Med Rehabil Clin N Am, 2006, 17(2): 287-302.
|
| 32 |
Wieseler-Frank J, Maier SF, Watkins LR. Immune-to-brain communication dynamically modulates pain: physiological and pathological Consequences [J]. Brain Behav Immun, 2005, 19(2): 104-111.
|
| 33 |
Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome [J]. Clin Rheumatol, 2007, 26(4): 465-473.
|
| 34 |
Melzack R, Coderre TJ, Katz J, et al. Central neuroplasticity and pathological pain [J]. Ann N Y Acad Sci, 2001, 933: 157-174.
|
| 35 |
Mayer TG, Neblett R, Cohen H, et al. The development and psychometric validation of the central sensitization inventory [J]. Pain Pract, 2012, 12(4): 276-285.
|
| 36 |
Neblett R, Cohen H, Choi Y, et al. The central sensitization inventory(CSI):establishing clinically signifificant values for identifying central sensitivity syndromes in an outpatient chronic pain sample [J]. J Pain, 2013, 14(5): 438-445.
|
| 37 |
Kim MS, Koh IJ, Sohn S, et al. Central sensitization is a risk factor for persistent postoperative pain and dissatisfaction in patients undergoing revision total knee arthroplasty [J]. J Arthroplasty, 2019, 34(8): 1740-1748.
|
| 38 |
Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits [J]. Annu Rev Neurosci, 1991, 14: 219-245.
|
| 39 |
Munro G. Dopamine D(1) and D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test [J]. Eur J Pharmacol, 2007, 575(1/3): 66-74.
|
| 40 |
Hsu ES. Acute and chronic pain management in fibromyalgia: updates on pharmacotherapy [J]. Am J Ther, 2011, 18(6): 487-509.
|
| 41 |
Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee [J]. Pain Pract, 2011, 11(1): 33-41.
|
| 42 |
Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial [J]. Age Ageing, 2012, 41(5): 646-652.
|
| 43 |
Wang G, Bi L, Li X, et al. Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study [J]. Osteoarthritis Cartilage, 2017, 25(6): 832-838.
|
| 44 |
Frakes EP, Risser RC, Ball TD, et al. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial [J]. Curr Med Res Opin, 2011, 27(12): 2361-2372.
|
| 45 |
王罡. 度洛西汀联合塞来昔布对膝关节骨关节炎疼痛的疗效分析 [J]. 中国疼痛医学杂志, 2018, 24(1): 77-80.
|
| 46 |
汪静，苏亚玲，张丛笑. 度洛西汀对慢性膝关节骨关节炎患者疼痛伴抑郁的疗效 [J]. 武警医学, 2018, 29(7): 715-717.
|
| 47 |
Sharma A GM, Safety OD. A dual serotonin and norepinephrine reuptake inhibitor [J]. J Clin Pharmacol, 2000, 40(2): 161-167.
|
| 48 |
Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a Meta-Analysis of randomized controlled trials [J]. Pain Med, 2015, 16(7): 1373-1385.
|
| 49 |
Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial [J]. Pain, 2009, 146(3): 253-260.
|
| 50 |
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia [J]. Cochrane Database Syst Rev, 2014, Jan 03(1): CD007115.
|
| 51 |
Koh IJ, Kim MS, Sohn S, et al. Duloxetine reduces pain and improves quality of recovery following total knee arthroplasty in centrally sensitized patients [J]. J Bone Joint Surg, 2019, 101(1): 64-73.
|
| 52 |
Blikman T, Rienstra W, Van Raaij TM, et al. Duloxetine in OsteoArthritis (DOA) study: study protocol of a pragmatic open-label randomised controlled trial assessing the effect of preoperative pain treatment on postoperative outcome after total hip or knee arthroplasty [J]. BMJ Open, 2016, 6(3): e010343.
|